New Delhi, April 25, 2023: Cadila Pharmaceutical’s ThRabis, the world’s first three-dose recombinant nano-particle-based rabies G protein vaccine, has made a significant contribution to the fight against rabies and making India rabies-free in the first year of its launch.
Cadila Pharmaceuticals launched its world’s first three-dose innovative rabies vaccine in April last year. This vaccine is an effort of Cadila Pharmaceuticals Limited towards supporting the initiative of the Government of India to make Rabies free India by 2030
Just one year down the road, more than 1 lakh vials of ThRabis have been consumed, translating to around 35,000 animal bite victims (3 doses per victim). ThRabis has been recommended by more than 10,000 doctors and 2,600 hospitals all over the country.
While reaching out to doctors and health professionals, Cadila Pharmaceuticals has also made conscious efforts to create greater awareness about rabies vaccination as a part of its commitment to make India rabies-free. It has reached out to more than 38 lakh people through various digital engagement initiatives.
ThRabis is a breakthrough vaccine and has successfully carved out a niche for itself in just one year. The vaccine has already contributed to saving many lives by helping prevent rabies-related deaths, but this is just the beginning. We are confident that ThRabis will prove to be a game-changer in the fight against rabies and help in eliminating rabies from the country by 2030 and world in the long run.
ThRabis won the top honour at the prestigious India Pharma World Awards last month when it was named the winner in the “Pharma Innovation of the Year Award” category. It is estimated that globally, rabies kills almost 60,000 animal bite victims every year. Over 20,000 people die in India alone, mainly because many animal bite victims do not complete the full course of the available vaccine.
Other approved rabies vaccines, which require five injections spread over 28 days, ThRabis is a three-dose vaccine administered within a week, ensuring clinical effectiveness. Before ThRabis was launched, many animal bite victims were unable to complete the full course of the vaccine due to the complex dosing schedule, frequent visits to the hospital, and potential loss of income associated with these visits, leaving many victims unprotected and susceptible to developing rabies. ThRabis’ simpler and more convenient regimen has helped in improving compliance to complete the vaccine course.
Corporate Comm India (CCI Newswire)
